RECRUITING

Rising Tide - Amniotic Tissue(s) Treatments for Chronic Diabetic Foot Ulcers

Talk to us

Conditions

Diabetic Foot Ulcer (DFU)Chronic Foot UlcersAmnionChorionAmnion Amnion GraftAmnion Chorion Amnion GraftsAmnion Chorion GraftDiabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesEndocrine System DiseasesPathologic ProcessesUlcerSkin UlcerChronic UlcerChronic Foot UlcerDiabetic AngiopathiesDiabetes Type 2Diabetes Type IILeg UlcerPlacental-Based AllograftsHuman Placental-Based Skin GraftsSkin Wound Covering

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this clinical investigation is to evaluate the safety and efficacy of Amnion/Chorion/Amnion allograft , Amnion/Chorion allograft, and/or Amnion/Amnion allograft, plus Standard of Care (SOC) each versus SOC alone in the treatment of chronic non-healing diabetic foot ulcers (DFU) after 12 weeks of treatment.

Official Title

A Multi-Center, Randomized Controlled Clinical Investigation Evaluating an Amnion/Chorion/Amnion Allograft, Amnion/Chorion Allograft, And/or an Amnion/Amnion Allograft Versus Standard of Care in the Treatment of Non-Healing Diabetic Foot Ulcers

Quick Facts

Study Start:2024-11-14
Study Completion:2026-11-18
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06681428

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. At least 18 years old, inclusive.
  2. 2. Presence of a DFU, Wagner Grade 1, extending through the dermis provided it is below the medial aspect of the malleolus.
  3. 3. The index ulcer (ulcer to be evaluated in the study) will be the largest ulcer if two or more DFUs are present with the same Wagner grade and will be the only one evaluated in the study. If other ulcerations are present on the same foot, they must be more than 2 cm distant from the index ulcer.
  4. 4. Index ulcer has been present for greater than 4 weeks prior to SV1 and less than 1 year, as of the date the subject consents for study.
  5. 5. Index ulcer is a minimum of 1.0 cm2 and a maximum of 25 cm2 at SV1 and TV1.
  6. 6. Within 3 months of SV1, adequate circulation to the affected foot as documented by a dorsal transcutaneous oxygen measurement (TCOM) or a skin perfusion pressure (SPP) measurement of ≥ 30 mmHg, or an Ankle Branchial Index (ABI) between 0.7 and 1.3 using the affected study extremity. As an alternative, arterial Doppler ultrasound can be performed evaluating for biphasic dorsalis pedis and posterior tibial vessels at the level of the ankle or a TBI (Toe Brachial Index) of \> 0.6 is acceptable.
  7. 7. The target ulcer has been offloaded for at least 14 days, prior to TV1.
  8. 8. Females of childbearing potential must be willing to use acceptable methods of contraception (birth control pills, barriers or abstinence) during the course of the study and undergo pregnancy tests.
  9. 9. Subject understands and is willing to participate in the clinical study and can comply with weekly visits.
  10. 10. Subjects must have read and signed the IRB approved ICF before screening procedures are performed.
  1. 1. Index ulcer(s) deemed by the investigator to be caused by a medical condition other than diabetes
  2. 2. Index ulcer, in the opinion of the investigator, is suspicious for cancer and should undergo an ulcer biopsy to rule out a carcinoma of the ulcer
  3. 3. Index ulcer is infected
  4. 4. Subjects with a history of more than two weeks of treatment with immune-suppressants (including systemic corticosteroids \>10mg daily dose), cytotoxic chemotherapy, or application of topical steroids to the ulcer surface within 1-month prior to first SV1, or who receive such medications during the screening period or who are anticipated to require such medications during the course of the study
  5. 5. Subjects on any investigational drug(s), Investigational products, or therapeutic device(s) within 30 days preceding SV1
  6. 6. History of radiation at the ulcer site (regardless of time since last radiation treatment)
  7. 7. Index ulcer has been previously treated or will need to be treated with any prohibited therapies
  8. 8. Subjects with a previous diagnosis of HIV or Hepatitis C
  9. 9. Presence of any condition(s) which seriously compromises the subject's ability to complete this study or has a known history of poor adherence with medical treatment
  10. 10. Osteomyelitis or bone infection of the affected foot as verified by x-ray within 30 days prior to the first screening visit. (In the event of an ambiguous diagnosis, the Principal Investigator will make the final decision)
  11. 11. Subject is pregnant or breast-feeding
  12. 12. Presence of diabetes with poor metabolic control as documented with an HbA1c \>12.0 within last 90 days
  13. 13. Subjects with end stage renal disease as evidenced by a serum creatinine ≥3.0 mg/dL within 6 months of enrollment
  14. 14. Presence of acute Charcot Neuroarthropathy to the affected limb
  15. 15. Index ulcer that has reduced in area by 30% or more after 14 days of SOC from SV1 to the TV1/Randomization visit

Contacts and Locations

Study Contact

Frank Burrows III, MBA, EMT, BCMAS, CWCA
CONTACT
888-494-4441
FBurrows@tidesmedical.com
Mora Melican, PH.D.
CONTACT
888-494-4441
MMelican@tidesmedical.com

Principal Investigator

David G Armstrong, DPM, MD, PhD
STUDY_CHAIR
Keck School of Medicine of USC
Frank Burrows, MBA, EMT, BCMAS, CWCA
STUDY_DIRECTOR
Tides Medical

Study Locations (Sites)

Limb Preservation Platform Inc
Fresno, California, 93710
United States
Angel City Research
Los Angeles, California, 90010
United States
Clemente Clinical Research
Los Angeles, California, 90033
United States
ILD Research Center
Vista, California, 92081
United States
Clever Medical Research
Miami, Florida, 33126
United States
Foot and Ankle Specialists of the Mid-Atlantic
Raleigh, North Carolina, 27609
United States
Lower Extremity Institute of Research and Therapy
Boardman, Ohio, 44512
United States
Brock Liden DPM
Circleville, Ohio, 43113
United States
Foot and Ankle Specialists of the Mid-Atlantic
Salem, Virginia, 24153
United States

Collaborators and Investigators

Sponsor: Tides Medical

  • David G Armstrong, DPM, MD, PhD, STUDY_CHAIR, Keck School of Medicine of USC
  • Frank Burrows, MBA, EMT, BCMAS, CWCA, STUDY_DIRECTOR, Tides Medical

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-11-14
Study Completion Date2026-11-18

Study Record Updates

Study Start Date2024-11-14
Study Completion Date2026-11-18

Terms related to this study

Keywords Provided by Researchers

  • Amnion
  • Chorion
  • Amnion Amnion Graft
  • Amnion Chorion Amnion Grafts
  • Amnion Chorion Graft
  • Diabetes Mellitus
  • Glucose Metabolism Disorders
  • Metabolic Diseases
  • Endocrine System Diseases
  • Pathologic Processes
  • Ulcer
  • Skin Ulcer
  • Chronic Ulcer
  • Chronic Foot Ulcer
  • Diabetic Angiopathies
  • Diabetes Type 2
  • Diabetes Type II
  • Leg Ulcer
  • Placental-Based Allografts
  • Human Placental-Based Skin Grafts
  • Skin Wound Covering

Additional Relevant MeSH Terms

  • Diabetic Foot Ulcer (DFU)
  • Chronic Foot Ulcers